What's hot

View all perspectives
      #1477 🔬Zasocitinib (TYK-2i) shows promise in phase IIb RCT

      ➡️n=290, randomised to PBO, 5/15/30mg gps

      💥30mg g

      Caoilfhionn Connolly CaoilfhionnMD

      9 months 3 weeks ago
      #1477 🔬Zasocitinib (TYK-2i) shows promise in phase IIb RCT ➡️n=290, randomised to PBO, 5/15/30mg gps 💥30mg group 📉 Rapid skin improvement @ Wk 2 ➡️Wk 12 PASI:~2X placebo (-2.5;p=0.004) 🛟Well tolerated ⬆️MDA (28 v. 12.5% p<0.05) promise for other PsA domains #ACR @RheumNow https://t.co/5GusMlVkQ4
      Exciting early data for new highly selective TYK2i zasocitinib

      Improved PASI skin scores (though not as much as IL23i..

      Mike Putman EBRheum

      9 months 3 weeks ago
      Exciting early data for new highly selective TYK2i zasocitinib Improved PASI skin scores (though not as much as IL23i...) Funky skin-related adverse events at higher doses, not sure what to make of that? #ACR24 @rheumnow Abstr#1477 https://t.co/CtOFsoHdBh
      T2T approaches in early PsA:
      -STAMP trial (open label, multicenter RCT) eval early SEC (300mg+ MTX15+ 80mg steroid injec

      Adela Castro AdelaCastro222

      9 months 3 weeks ago
      T2T approaches in early PsA: -STAMP trial (open label, multicenter RCT) eval early SEC (300mg+ MTX15+ 80mg steroid injection) vs SoC (MTX25+80mg steroid injection) -At week 12, 38% pts on SEC vs 17% on SoC achieved ACR50. Also did better on MDA & PASI. -No significant… https://t.co/MflI3d0FqV https://t.co/RjnzeaTyQK
      How do you treat a flare of SLE with steroids?

      @RheumNow #ACR24

      Eric Dein ericdeinmd

      9 months 3 weeks ago
      How do you treat a flare of SLE with steroids? @RheumNow #ACR24
      Petri: 5 mg prednisone or less is our standard for lupus control

      EULAR 23 recs - early addition of immunosuppressant an

      Eric Dein ericdeinmd

      9 months 3 weeks ago
      Petri: 5 mg prednisone or less is our standard for lupus control EULAR 23 recs - early addition of immunosuppressant and/or biologics instead to prevent steroids @RheumNow #ACR24 @jhrheumatology https://t.co/jhxEeboPu5
      RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Bristol Myers Squibb and UCB. All content i

      Dr. John Cush RheumNow

      9 months 3 weeks ago
      RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty
      New agent on the block: Bimekizumab IL-17A/F inhibitor

      Promising clinical data in SpA - what about imaging findings?

      D

      Brian Jaros, MD Dr_Brian_MD

      9 months 3 weeks ago
      New agent on the block: Bimekizumab IL-17A/F inhibitor Promising clinical data in SpA - what about imaging findings? Dramatic reductions in MRI activity at SI joints seen in BKZ pt, esp when compared to trajectory of PBO pt before cross-over @RheumNow #ACR24 Abst #1757 https://t.co/ACLJx5XkyN
      At "Envisioning a Steroid Free Future" talk

      Angelo Gaffo at the mic: "Are there any situations you would do induction t

      Mike Putman EBRheum

      9 months 3 weeks ago
      At "Envisioning a Steroid Free Future" talk Angelo Gaffo at the mic: "Are there any situations you would do induction therapy for AAV without steroid?" John Stone: [pause] "No." 😄 #ACR24 @RheumNow
      #1462 🔬Rx persistence in PsA; Guselkumab (GUS) v. IL17Ai

      💡 GUS (n=910) persistence @ 12 months (67%) almost 2X IL

      Caoilfhionn Connolly CaoilfhionnMD

      9 months 3 weeks ago
      #1462 🔬Rx persistence in PsA; Guselkumab (GUS) v. IL17Ai 💡 GUS (n=910) persistence @ 12 months (67%) almost 2X IL-17Ai (n=2743) (50%) ⏳ Median time to discontinuation: GUS not reached v 12.3 months for IL-17Ai. 🔴Durable therapy ❓better outcomes #ACR @RheumNow https://t.co/LfA3WygNVq
      Reset the bar for remission (off steroids)!! Session #17S19

      3% higher risk of organ damage for each 1mg of pred

      Remiss

      Jiha Lee JihaRheum

      9 months 3 weeks ago
      Reset the bar for remission (off steroids)!! Session #17S19 3% higher risk of organ damage for each 1mg of pred Remission possible in rheum with lower dose GC regimen and faster taper #GCStewardship #ACR24 @RheumNow @BethIWallace
      Single centre experience of belimumab at @GSTTnhs

      @RheumNow #ACR24 https://t.co/c4jlEPRwen

      Mrinalini Dey DrMiniDey

      9 months 3 weeks ago
      Single centre experience of belimumab at @GSTTnhs @RheumNow #ACR24 https://t.co/c4jlEPRwen
      In case you needed more encouragement for recombinant zoster vaccination in RA patients:
      it prevents herpes zoster episo

      David Liew drdavidliew

      9 months 3 weeks ago
      In case you needed more encouragement for recombinant zoster vaccination in RA patients: it prevents herpes zoster episodes, in the real world. RA pts in KP system n=1926 vaccinated matched 1:3 with non-vaccinated - HZ reduced 60% - PHN reduced 88% #ACR24 ABST0977 @RheumNow https://t.co/BryBrlv9K5
      Petri on Steroids in SLE
      Steroid-related organ damage presents later
      - organ damage is higher in African-Americans
      Dose

      Eric Dein ericdeinmd

      9 months 3 weeks ago
      Petri on Steroids in SLE Steroid-related organ damage presents later - organ damage is higher in African-Americans Dose response for prednisone and CVD risk Each 1 mg prednisone = 3% increase risk in organ damage! #ACR24 @jhrheumatology @RheumNow https://t.co/00S1mxrXJp
      Appreciate the conversation with Dr Ana-Maria Orbai @jhrheumatology on abstract#0600 on bimekizumab PRO data

      https://t.

      Eric Dein ericdeinmd

      9 months 3 weeks ago
      Appreciate the conversation with Dr Ana-Maria Orbai @jhrheumatology on abstract#0600 on bimekizumab PRO data https://t.co/86J4HWKeIv @RheumNow #ACR24 https://t.co/QYqj5rKHIH
      A systematic review reveals significant sex-related differences in efficacy and safety outcomes in axial spondyloarthrit

      Antoni Chan MD (Prof) synovialjoints

      9 months 3 weeks ago
      A systematic review reveals significant sex-related differences in efficacy and safety outcomes in axial spondyloarthritis (axSpA) trials. Males show higher response rates to advanced therapies compared to females. Out of 79 RCTs, only a fraction reported sex-disaggregated data.… https://t.co/dkMRK4ZYHF
      How well do you know this week's rheumatology news?
      Take the rheumIQ quiz
      Take the RheumIQ Quiz

      Podcasts

      • ACR24 IL-17 Topic Panel Advancing Care with IL-17 Pathway Insights
      • ACR24 JAK TYK Topic Panel
      • RheumNow Day 1 Recap ACR Convergence 2024 Highlights

      Catch up on Conference Podcasts

      ×